Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans.
about
Do glucagonomas always produce glucagon?Efficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trial.Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study.The intestinal distribution pattern of appetite- and glucose regulatory peptides in mice, rats and pigs.Glucagon sensitivity and clearance in type 1 diabetes: insights from in vivo and in silico experiments.Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes.Comparison of sitagliptin with nateglinide on postprandial glucose and related hormones in drug-naïve Japanese patients with type 2 diabetes mellitus: A pilot study.Noncompetitive affinity assays of glucagon and amylin using mirror-image aptamers as affinity probes.Postabsorptive hyperglucagonemia in patients with type 2 diabetes mellitus analyzed with a novel enzyme-linked immunosorbent assay.Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.Islet α cells and glucagon--critical regulators of energy homeostasis.2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 2 - Hybrid LBA/LCMS and input from regulatory agencies).Dynamics of glucagon secretion in mice and rats revealed using a validated sandwich ELISA for small sample volumes.Stability of glucagon-like peptide 1 and glucagon in human plasma.Development of a high-throughput UHPLC-MS/MS (SRM) method for the quantitation of endogenous glucagon from human plasma.Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion.The GLP-1 response to glucose does not mediate beta and alpha cell dysfunction in Hispanics with abnormal glucose metabolism.Characterization and quantification of oxyntomodulin in human and rat plasma using high-resolution accurate mass LC-MS.Suppression of Extrapancreatic Glucagon by Octreotide May Reduce the Fasting and Postprandial Glucose Levels in a Diabetic Patient after Total Pancreatectomy.The role of glucagon in weight loss-mediated metabolic improvement: a systematic review and meta-analysis.2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 2 - hybrid LBA/LCMS and input from regulatory agencies).Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study.The preanalytical stability of glucagon as measured by liquid chromatography tandem mass spectrometry and two commercially available immunoassays.The impact of EndoBarrier gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes.The biology of glucagon and the consequences of hyperglucagonemia.Genetic determinants of circulating GIP and GLP-1 concentrations.Accurate analytical method for human plasma glucagon levels using liquid chromatography-high resolution mass spectrometry: comparison with commercially available immunoassays.Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levels.The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetesHyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies
P2860
Q26771665-2803F974-1233-4EAF-ACA3-525033CB6B19Q35225372-CC97F8D9-7322-429F-8C21-3B76BB9C62AFQ35772580-B87FAD36-C5E1-4E41-8F9C-03B93A275020Q35910048-75974920-BF47-42CD-AB4A-186714839632Q36017577-93B78035-8C77-4B55-8C3D-8E158F4CFCC8Q36031120-1E8472AC-B251-4395-829D-E2081D5AB48BQ36082252-8BAFC795-65D8-469C-9FB8-DD6A7D0D5E79Q36665222-4F08CF7E-0F99-4C62-95F2-C5C70B9184BFQ36843873-89B5340F-5C67-4DA2-A57B-DBBFD591C5ADQ37613876-F605D2AD-3A64-4B6B-8010-FBB7680F3A2AQ38409880-66345432-703C-477B-8CFE-1615CF26112BQ39010880-52228ECC-C08B-4432-8495-D7A291197B00Q39721905-4D488A02-D8B0-4E01-A09F-43EF2C45E93DQ41571544-3A7834BB-62F6-4BA9-906A-8D8605EC6515Q41656530-1B30A71E-2336-4483-B16D-42E464D22B08Q42128258-FCDEFA03-2CE6-4B41-B576-138B8A467497Q46250756-F29F10DE-09B5-41E3-BA12-97D022593C23Q46531147-F0924A96-9733-4431-80BC-26116D160EB9Q47104003-FC27D84D-6F61-492A-8F9E-D6FE818B9BDBQ47176353-49BA9E07-5F3D-4F65-907C-A65C49901DAEQ47894816-EDF5CC92-62E3-4DD4-BC42-A99CB8A1452EQ48264817-2E251D32-A058-4D5B-8628-015410E46328Q50277648-0E015D7E-1355-49D9-BC66-5BCD8546864FQ51437800-8EBDB818-6855-4DA1-8BA3-3B87013D3F8DQ51525761-BBFCCF49-B27B-4811-9A07-6F36F19C51F4Q52837850-A4826775-E350-45F1-ADEF-4273563E6E4CQ53114917-00EB288A-4A34-4C1B-A477-2C4AB6F4FE6AQ53360148-3A08D5A6-9DA3-42CB-8638-5143F63219BFQ57637770-5FEC4743-9C98-4CCF-ABAD-5D3D112F4464Q58167548-61932A3C-541F-4C77-86E0-11507AE5C394Q58447614-48A11021-7FD1-4A28-9551-739468C0E2B2
P2860
Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Specificity and sensitivity of ...... modulin measurement in humans.
@en
Specificity and sensitivity of ...... modulin measurement in humans.
@nl
type
label
Specificity and sensitivity of ...... modulin measurement in humans.
@en
Specificity and sensitivity of ...... modulin measurement in humans.
@nl
prefLabel
Specificity and sensitivity of ...... modulin measurement in humans.
@en
Specificity and sensitivity of ...... modulin measurement in humans.
@nl
P2093
P50
P356
P1476
Specificity and sensitivity of ...... modulin measurement in humans.
@en
P2093
Filip K Knop
Jens Pedersen
Monika J Bak
P304
P356
10.1530/EJE-13-0941
P50
P577
2014-03-08T00:00:00Z